ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results ZyVersa Therapeutics (OTCQB: ZVSA) reported Q3 2025 results for the quarter ended September 30, 2025. Cash on hand was $0.5 million and the company said existing cash will only fund month-to-month operations, requiring additional financing. ZyVersa raised approximately $2.05 million in Q3 and $4.05 million year-to-date. Research and development expenses were $0.4 million (down 16.3% YoY); general and administrative expenses were $1.7 million (down 5.1% YoY). Pre-tax loss was $20.7 million driven mainly by an $18.6 million impairment of in-process R&D. Net loss was $19.8 million; a deferred tax benefit of $0.9 million related to the impairment was recorded.

#ZVSA ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ZVSA/zy-versa-thera...

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones ZyVersa Therapeutics (OTCQB: ZVSA) reported Q2 2025 financial results and provided updates on its key drug development programs. The company activated its first clinical site for Phase 2a trial of VAR 200 in diabetic kidney disease (DKD) patients in June 2025, with interim results expected in Q4-2025. ZyVersa raised $2.05 million post-Q2 and $4.05 million year-to-date.The company is advancing two main programs: VAR 200 for kidney diseases and IC 100 for inflammatory conditions. An IND-enabling obesity study for IC 100 is planned for Q4-2025. Financial results show Q2 2025 net losses of $2.2 million, improved from $2.8 million in Q2 2024, with cash on hand of $0.1 million as of June 30, 2025. The company requires additional financing to support ongoing operations and meet stated milestones. [ "Secured $12 million in capital access through financing transactions", "Net loss improved by 20% year-over-year to $2.2 million in Q2 2025", "R&D expenses decreased by 42.2% year-over-year", "G&A expenses reduced by 20.1% compared to Q2 2024", "Advancing two promising drug candidates in large market opportunities ($30B kidney disease and $186B inflammatory disease markets by 2034)" ]

#ZVSA ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

www.stocktitan.net/news/ZVSA/zy-versa-thera...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks oversold with improving relative strength, Wed Jul 23rd - #ZVSA #MLAB #CLSD #FOXO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress ZyVersa Therapeutics (NASDAQ:ZVSA) released a mid-year shareholder letter highlighting recent developments and R&D progress. The company secured $12 million in financing through two transactions: a $2M warrant inducement and a $10M Share Purchase Agreement. Their lead programs include VAR 200 for kidney diseases, currently in Phase 2a trials for diabetic kidney disease (DKD) with preliminary data expected in Q4-2025, and IC 100, an inflammasome inhibitor targeting obesity with cardiometabolic comorbidities.The company recently transitioned to trading on the OTC Market while maintaining its ZVSA ticker. ZyVersa is advancing its clinical programs amid challenging biotech market conditions, with key milestones expected in H2 2025, including preliminary DKD trial data and initiation of IND-enabling preclinical studies for IC 100.

#ZVSA ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

www.stocktitan.net/news/ZVSA/zy-versa-thera...

News; ( NASDAQ: #ZVSA ) ZyVersa Backs FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in Patient with ApoCII Amyloidosis

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds ZyVersa Therapeutics (Nasdaq: ZVSA), a clinical stage biopharmaceutical company, has entered into a warrant inducement agreement with a single institutional investor. The agreement includes the immediate exercise of existing Series A-2 and A-3 Warrants at a reduced exercise price of $0.67, generating gross proceeds of $2.0 million.In exchange for exercising the existing warrants, the investor will receive new Series A-4 unregistered warrants to purchase up to 6,124,930 shares of common stock in a private placement. The new warrants will have an exercise price of $0.67 and will expire five years from stockholder approval. The transaction is expected to close around July 9, 2025.

#ZVSA ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

www.stocktitan.net/news/ZVSA/zy-versa-thera...

Digital medical illustration of kidneys with inflammation, representing kidney disease research and treatment innovation by ZyVersa Therapeutics.

Compassionate use approved: A patient with ultra-rare ApoCII amyloidosis is now receiving #ZyVersa #ZVSA investigational kidney drug VAR 200 under FDA emergency authorization. A bold step in precision medicine and a hopeful sign for those with no other options.
prismmarketview.com/zyversa-ther...

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis ZyVersa Therapeutics (NASDAQ:ZVSA) has received FDA authorization for Emergency Compassionate Use of its Cholesterol Efflux Mediator™ VAR 200 in a patient with ApoCII amyloidosis, an ultra-rare kidney condition. The treatment will be administered at the University of Miami under the care of Dr. Alessia Fornoni, who is also the inventor of VAR 200.The patient, who has shown continued kidney disease progression despite standard treatments, will receive VAR 200 following the protocol of the ongoing Phase 2a diabetic kidney disease (DKD) clinical trial. The drug was selected due to evidence of lipid deposition in the patient's kidney biopsy and VAR 200's demonstrated ability to reduce renal lipid accumulation in preclinical studies.

#ZVSA ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

www.stocktitan.net/news/ZVSA/zy-versa-thera...

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases ZyVersa Therapeutics (NASDAQ: ZVSA) highlights a new study published in Nature's Experimental and Molecular Medicine that reinforces the role of microglia-driven inflammation in Parkinson's and Alzheimer's diseases. The study validates ZyVersa's recent research showing how their Inflammasome ASC Inhibitor IC 100 could potentially modify disease progression by inhibiting NLRP1 inflammasome activation and reducing toxic phosphorylated alpha-synuclein levels. The global Parkinson's treatment market, currently valued at $6.6 billion (2024), is projected to reach $13.3 billion by 2034. The research, funded by the Michael J. Fox Foundation and conducted at the University of Miami School of Medicine, demonstrated that inflammatory microglia triggered pathological features of neurodegenerative diseases, including abnormal protein accumulation and neuroinflammation. ZyVersa plans to initiate proof-of-concept studies in Parkinson's disease animal models later this year.

#ZVSA ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases

www.stocktitan.net/news/ZVSA/zy-versa-thera...

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress ZyVersa Therapeutics (NASDAQ: ZVSA) reported Q1 2025 financial results and pipeline updates. The company posted a net loss of $2.3M, showing a 20.2% improvement from Q1 2024. Key developments include: 1) Phase 2a trial for VAR 200 in diabetic kidney disease to begin by Q2-end 2025; 2) Obesity-related preclinical study for IC 100 planned for Q2-end 2025; 3) IND application for IC 100 expected in H2 2025. The company raised $2.0M in Q1 but reports only $1.6M cash on hand, requiring additional financing for operations. R&D expenses decreased 49.5% to $259K, while G&A expenses dropped 18.5% to $1.9M. Recent data showed IC 100's potential in treating Parkinson's disease by blocking microglial inflammasome activation and reducing alpha-synuclein accumulation.

#ZVSA ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

www.stocktitan.net/news/ZVSA/zy-versa-thera...

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update ZyVersa Therapeutics (ZVSA) reported its full year 2024 financial results and provided pipeline updates. The company plans to begin a Phase 2a clinical trial for VAR 200 in diabetic kidney disease patients in H1-2025, and expects to submit an IND for IC 100 in H2-2025.Key financial highlights include:Net loss of $9.4 million for 2024, improved 90.4% from $98.3 million in 2023R&D expenses decreased 44.5% to $1.8 millionG&A expenses reduced 34.4% to $7.4 millionRaised approximately $6.6 million in 2024 and $2.0 million in Q1-2025The company's cash position of $1.5 million as of December 31, 2024, will fund operations on a month-to-month basis, requiring additional financing to support continuing operations and meet stated milestones.

#ZVSA ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/ZVSA/zy-versa-thera...

Healthcare Fund Backs ZyVersa With $2M Investment: Key Terms Revealed Healthcare-focused institutional investor commits $2M through share purchase at $0.95 and warrants at $1.00. Deal includes repricing of existing warrants.

#ZVSA ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

www.stocktitan.net/news/ZVSA/zy-versa-thera...

#SXTP #TCBP #ZVSA #BCAN

LETS GET IT!

#Stocks #StockMarket #Invest

Just In: ( NASDAQ: #ZVSA ) ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco

#StockMarket #News

#ZVSA ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/ZVSA/zy-versa-thera...

Breaking News: ( NASDAQ: #ZVSA ) ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

#StockMarket #News

SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL Getting your Trinity Audio player ready... Investors seeking promising opportunities in the biotech and tech sectors should keep an eye on several companies showing potential for significant market tu...

(9) SmallCap Biotech & Tech Companies To Watch
thestreetreports.com/10-smallcap-...
#PRSO #ZVSA #DYAI #RLMD #VTAK #INBS #KAVL